Cinryze (C1-inhibitor) for the treatment of hereditary angioedema.
Author(s): Gompels MM, Lock RJ.
Affiliation(s): Immunology and Immunogenetics, Pathology Sciences, North Bristol NHS Trust,
Southmead Hospital, Bristol, BS10 5NB, UK. mark.gompels@nbt.nhs.uk
Publication date & source: 2011, Expert Rev Clin Immunol. , 7(5):569-73
Cinryze is a pasteurized, nanofiltered plasma derived concentrate of C1-inhibitor
(pdC1-INH) licensed for the prophylactic treatment of hereditary angioedema. In a
double-blind placebo-controlled crossover trial to evaluate Cinryze as
prophylaxis, the frequency of attacks was halved (6.26 per 12 weeks on Cinryze
versus 12.73 per 12 weeks on placebo). Furthermore, attacks were generally milder
and of shorter duration. For treatment of acute attacks in patients receiving
Cinryze, 1000 units, within 4 h of the start of an attack, the estimated time to
the onset of unequivocal relief was reduced to 2 h, compared with more than 4 h
in those treated with placebo. Cinryze and other similar products are going to
change the future management of hereditary angioedema and have potential in other
areas of medicine.
|